About Mepsgen
Mepsgen is a company based in Seoul (South Korea) founded in 2019 by Yongtae Kim. Mepsgen has raised $29.26 million across 4 funding rounds from investors including Korean Development Bank, Yuanda Financial Holdings and KB Investment. Mepsgen offers products and services including MEPS-X, MST-X, and NanoCalibur. Mepsgen operates in a competitive market with competitors including Emulate, CN Bio, AxoSim, Mimetas and Nortis, among others.
- Headquarter Seoul, South Korea
- Founders Yongtae Kim
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website mepsgen.com
- Social LinkedIn
- Legal Name Mepsgen Co., Ltd.
- Total Equity Funding$29.26M (USD)
in 4 rounds
- Latest Funding Round$14.84M (USD), Series C
Nov 2024
- InvestorsKorean Development Bank
& 6 more
Products & Services of Mepsgen
Mepsgen offers a comprehensive portfolio of products and services, including MEPS-X, MST-X, and NanoCalibur.
Automated platform for modeling human tissue barriers in drug testing
Tools for scalable production of lipid nanoparticles
Automated system for nanoparticle manufacturing from lab to GMP scale
Funding Insights of Mepsgen
Mepsgen has successfully raised a total of $29.26M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $14.84 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $29.26M
- Total Rounds 4
- Last Round Series C — $14.84M
- First Round $2.94M
(Aug 2020)
- Investors Count 7
All 4 funding rounds of Mepsgen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2024 | $14.84M | Series C | – | Yuanda Financial Holdings, KB Investment | |
| Jul 2022 | $8.02M | Series B | – | – | – |
| Aug 2021 | $3.47M | Series A | – | – | – |
| Aug 2020 | $2.94M | Series A | – | – | – |
7 investors in total: 6 institutional and 1 angel.
Investors in Mepsgen
Mepsgen has secured backing from 7 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Korean Development Bank, Yuanda Financial Holdings and KB Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund investing in early-stage tech startups | 1990 | kbic.co.kr | Seoul, South Korea | |
- | – | eninvestment.co.kr | - | |
Sector-agnostic VC firm investing in geographies such as South Korea | 1986 | sbik.co.kr | Seoul, South Korea | |
Financial services provider | 1961 | yuanta.com | Taipei, Taiwan | |
Development financing and commercial banking are provided in South Korea. | 1954 | kdb.co.kr | Seoul, South Korea | |
NH Nam Ho Kim | - | – | unknown_8bc9fd6069d44fe49 | - |
Provider of live cell imaging system | 2004 | lcibio.com | Seoul, South Korea |
Investor details for Mepsgen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Mepsgen
1 people are tracked at Mepsgen (1 in leadership).
| Name | Role | Group |
|---|---|---|
Yongtae Kim | Co-Founder & CEO | Leadership |
Complete people profiles for Mepsgen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Mepsgen
3 dated milestones of Mepsgen across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Mepsgen is founded.
- Funding First funding round of $2.9M.
- Funding Latest funding round, Series C, of $14.8M.
Competitors of Mepsgen
Mepsgen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Emulate, CN Bio, AxoSim, Mimetas and Nortis, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| emulatebio.com | 2013 | Boston, United States | $204.49M | 93 | Developer of in vitro models for drug development | |
| cn-bio.com | 2009 | Cambridge, United Kingdom | $44.78M | 33 | Organ-on-a-chip platforms are developed for drug discovery applications. | |
| axosim.com | 2014 | New Orleans, United States | $6.78M | 27 | Nerve-on-a-chip technology is advanced by AxoSim for drug development improvement. | |
| mimetas.com | 2013 | Leiden, Netherlands | $28.9M | – | Microfluidics-based organ-on-a-chip models for drug evaluation are developed. | |
| nortisbio.com | 2007 | Woodinville, United States | $10.66M | 19 | Small human tissue segments are generated in microfluidic chips. | |
| netri.com | 2018 | Lyon, France | $8.89M | – | Microfluidic devices are developed for industrial applications and brain-on-a-chip models. | |
| obatalasciences.com | 2017 | New Orleans, United States | $3.54M | 10 | Provider of research enabling products and services to research centers | |
| cellboxlabs.com | 2020 | Riga, Latvia | $1.01M | 10 | Organ-on-chip platform is provided for drug discovery and development. | |
| hesperosinc.com | 2015 | Orlando, United States | – | 15 | Organ-on-a-chip solutions for preclinical testing are developed. |
Detailed competitors of Mepsgen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Mepsgen
The website of Mepsgen (mepsgen.com) receives about 3.1K visits a month.
- Monthly visits3.1K
▲ 564.1% vs previous month
Latest news on Mepsgen
Complete news archive for Mepsgen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Mepsgen
10 companies that operate in the same segment as Mepsgen (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Mepsgen
Mepsgen was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Mepsgen is headquartered in Seoul, South Korea.
Yongtae Kim is the current CEO of Mepsgen. They have also founded this company.
Mepsgen is a funded company, having raised a total of $29.26M across 4 funding rounds to date. The company's 1st funding round was a Series A of $2.94M, raised on Aug 2020.
Developer of human organ model chips for pharmaceutical development. The company develops and produces a 3D cell cultures organ-on-a-chip platform such as the MEPS-X series and MG-X series to develop drug candidates which target Alzheimers and brain tumors.
Mepsgen's top competitors include Emulate, CN Bio and Cellbox Labs.
Mepsgen offers MEPS-X, MST-X, and NanoCalibur.
Mepsgen has 7 investors. Key investors include Korean Development Bank, Yuanda Financial Holdings, KB Investment, SBI Investment Korea, and Live Cell Instrument.
Mepsgen operates through Mepsgen Co., Ltd..